Clinical Report: Phase 1 Trial of ABBV-706 in Advanced Small Cell Lung Cancer

Overview

The phase 1 trial of ABBV-706 demonstrated a manageable safety profile and promising antitumor activity in patients with advanced solid tumors, particularly those with relapsed/refractory small cell lung cancer (SCLC). The trial achieved an overall response rate (ORR) of 43.8%, with a notable 60.9% ORR in patients with relapsed/refractory SCLC, indicating a significant therapeutic potential for this challenging patient population.

Background

Small cell lung cancer (SCLC) is an aggressive malignancy characterized by rapid growth and early metastasis, leading to a poor prognosis. The 5-year overall survival rate for patients with extensive-stage SCLC is approximately 12%, highlighting the urgent need for innovative therapies. Current treatment options, including chemotherapy and radiation, often result in rapid disease progression and limited long-term survival. ABBV-706, an antibody-drug conjugate targeting the seizure-related homolog protein 6 (SEZ6), represents a novel therapeutic approach aimed at addressing this unmet medical need by selectively delivering cytotoxic agents to cancer cells expressing SEZ6.

Data Highlights

{'Overall Response Rate (ORR)': '43.8% (overall), 60.9% (in R/R SCLC)', 'Median Duration of Response': '5.6 months', 'Disease Control Rate': '70.2%', 'Progression-Free Survival (PFS)': '4.2 months'}

Key Findings

The trial results indicate that ABBV-706 has a favorable safety profile, with manageable adverse events. The overall response rate of 43.8% suggests that a significant proportion of patients benefit from treatment. The median duration of response was recorded at 5.6 months, and the disease control rate reached 70.2%, indicating that ABBV-706 effectively stabilizes disease in a majority of patients. Additionally, the median progression-free survival (PFS) of 4.2 months provides further evidence of the drug's potential efficacy in this difficult-to-treat population.

Clinical Implications

The promising efficacy of ABBV-706 in relapsed/refractory SCLC suggests it may serve as a valuable treatment option for patients who have limited alternatives. Given the high response rates observed, clinicians should consider incorporating SEZ6-targeting therapies into their treatment strategies for advanced SCLC. This approach may offer new hope for patients who have exhausted other treatment options and highlight the importance of continued research into targeted therapies for SCLC.

Conclusion

ABBV-706 shows significant promise as a novel therapeutic agent for patients with advanced SCLC, warranting further investigation in larger clinical trials to confirm its efficacy and safety. The results from this phase 1 trial provide a strong foundation for future studies aimed at optimizing treatment regimens and improving outcomes for patients with this challenging disease.

Related Resources & Content

1. The ASCO Post, HER3-Targeted Antibody-Drug Conjugate for Treatment-Resistant Solid Tumors, 2025 -- HER3-Targeted Antibody-Drug Conjugate for Treatment-Resistant Solid Tumors

2. The ASCO Post, EGFR-HER3 Bispecific Antibody-Drug Conjugate in Locally Advanced or Metastatic Solid Tumors, 2024 -- EGFR-HER3 Bispecific Antibody-Drug Conjugate in Locally Advanced or Metastatic Solid Tumors

3. The ASCO Post, Clinical Trials Study the Role of Immunotherapy in the First-Line Setting of Non–Small Cell Lung Cancer, 2017 -- Clinical Trials Study the Role of Immunotherapy in the First-Line Setting of Non–Small Cell Lung Cancer

4. The ASCO Post, Antibody-Drug Conjugate Makes Strong Showing in Small Cell Lung Cancer, 2015 -- Antibody-Drug Conjugate Makes Strong Showing in Small Cell Lung Cancer

5. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide, Journal of Clinical Oncology -- Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide

6. FDA grants accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer, FDA -- FDA grants accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer

7. Seizure-Related Homolog Protein 6 (SEZ6): Biology and Therapeutic Target in Neuroendocrine Carcinomas, PubMed -- Seizure-Related Homolog Protein 6 (SEZ6): Biology and Therapeutic Target in Neuroendocrine Carcinomas

8. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133) | Journal of Clinical Oncology

9. FDA grants accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer | FDA

10. Seizure-Related Homolog Protein 6 (SEZ6): Biology and Therapeutic Target in Neuroendocrine Carcinomas - PubMed